Liver Transplantation After Downstaging of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Using Yttrium‐90 Radioembolization: Pipe Dream or Reality?
Neil Mehta, Francis Y. Yao – 15 September 2021
Combination of Donor Anthropometrics With Recipient Imaging to Improve Matching in Liver Transplantation
Pietro Addeo, Philippe Bachellier, Vincent Noblet – 15 September 2021
Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective
Sarah R. Lieber, Hannah P. Kim, Luke Baldelli, Rebekah Nash, Randall Teal, Gabrielle Magee, Chirag S. Desai, Marci M. Loiselle, Simon C. Lee, Amit G. Singal, Jorge A. Marrero, A. Sidney Barritt, Donna M. Evon – 15 September 2021 – Survivorship after liver transplantation (LT) is a novel concept providing a holistic view of the arduous recovery experienced after transplantation. We explored components of early survivorship including physical, emotional, and psychological challenges to identify intervention targets for improving the recovery process of LT recipients and caregivers.
Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
Tetsuya Hosaka, Fumitaka Suzuki, Mariko Kobayashi, Shunichiro Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada – 15 September 2021 – Serum hepatitis B core‐related antigen (HBcrAg) and surface antigen (HBsAg) are surrogate markers of intrahepatic covalently closed circular DNA. The measurement range of the current HBcrAg assay is relatively narrow.
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
Fei Luo, Federico Oldoni, Avash Das – 15 September 2021 – Transmembrane 6 superfamily member 2 (TM6SF2) is located on chromosome 19 (19p12) and encodes for a protein of undetermined function. Genetic studies have reported the association between a nonsynonymous variant in TM6SF2 (E167K, rs58542926) with hepatic triglyceride content and its impact on the cardiovascular system. Clinical and epidemiological studies have confirmed the role of TM6SF2 in the development of nonalcoholic fatty liver disease (NAFLD).
Masthead
14 September 2021
Frailty is associated with increased risk of cirrhosis disease progression and death
- Read more about Frailty is associated with increased risk of cirrhosis disease progression and death
Sarah Wang, Reid Whitlock, Chelsea Xu, Sunil Taneja, Surender Singh, Juan G. Abraldes, Kelly W. Burak, Robert J. Bailey, Jennifer C. Lai, Puneeta Tandon – 14 September 2021
Hepatology Highlights
Iman Waheed Khan, Muhammad Ashar Ali, Daryl T.Y. Lau, Thuy‐Van P. Hang, Preeti A. Reshamwala, Nidhi Jalan‐Sakrikar, Robert E. Schwartz, Shalil Khanal, Enis Kostallari, Anthony J. Choi, Robert S. Brown, Adebowale O. Bamidele, Davide Povero, Wei Zhang, Alyson Kaplan, Jeremy Louissaint, Nabeel Wahid, Jessica L. Maiers – 14 September 2021
Letter to the editor: Autoimmune hepatitis after COVID‐19 vaccination: A rare adverse effect?
Panagiota Palla, Chrysovalantis Vergadis, Stratigoula Sakellariou, Theodoros Androutsakos – 14 September 2021
Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial
Björn Nashan, Peter Schemmer, Felix Braun, Hans J. Schlitt, Andreas Pascher, Christian G. Klein, Ulf P. Neumann, Irena Kroeger, Peter Wimmer, Hephaistos Study Group – 14 September 2021 – Everolimus‐facilitated reduced‐exposure tacrolimus (EVR + rTAC) at 30 days after liver transplantation (LT) has shown advantages in renal preservation. This study evaluated the effects of early initiation of EVR + rTAC in de novo LT recipients (LTRs).